SCHEMBL2864473

SCHEMBL2864473

Cc1ccc(O)cc1-n1nc2c(c1N)c(=O)[nH]c1cc(OCCN3CCOCC3)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
FGFR1 P11362 2/20 0.46
PDGFRB P09619 1/20 0.46
KDR P35968 1/20 0.46
JAK2 O60674 1/20 0.43
PARP1 P09874 2/20 0.43
FGFR2 P21802 1/20 0.43
FGFR3 P22607 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ESR1 P03372 2/20 0.41
CHUK O15111 2/20 0.41
INSR P06213 2/20 0.41
MAPK8 P45983 2/20 0.41
CAMKK2 Q96RR4 2/20 0.41
NPC1 O15118 2/20 0.40
CHEK1 O14757 1/20 0.40
ACHE P22303 1/20 0.40
ESR2 Q92731 2/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870232 0.96 MAOA (0.43) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2865389 0.92 KDM4E (0.50) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2862095 0.91 MAOA (0.47) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2861641 0.91 JAK2 (0.50) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2866738 0.91 MAOA (0.47) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2868581 0.88 KDM4E (0.49) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2864613 0.87 JAK2 (0.46) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2864429 0.86 MAOA (0.40) MAOAPARP1KDM4EESR1ESR2
SCHEMBL2868613 0.86 FGFR1 (0.49) MAOAFGFR1PDGFRBKDRJAK2
SCHEMBL2865177 0.84 FGFR1 (0.45) MAOAFGFR1PDGFRBKDRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US claimed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP claimed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAOA 2993/4885FGFR1 201/4885PDGFRB 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.